{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:39Z","timestamp":1793306019947,"version":"4.5.0"},"reference-count":25,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff\/day (= 100 \u03bcL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 \u00d7 3 puffs\/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting.<\/jats:p>","DOI":"10.3390\/brainsci7050047","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T13:42:06Z","timestamp":1493214126000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols"],"prefix":"10.3390","volume":"7","author":[{"given":"Ahmad","family":"Kanaan","sequence":"first","affiliation":[{"name":"Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany"},{"name":"Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstra\u00dfe 1a, Leipzig 04103, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgeni","family":"Jakubovski","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7181-7419","authenticated-orcid":false,"given":"Kirsten","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[{"name":"Clinic of Psychiatry, Socialpsychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","article-title":"The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: A cross-cultural perspective","volume":"67","author":"Robertson","year":"2009","journal-title":"J. Psychosom. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pediatrneurol.2011.03.003","article-title":"Prevalence of Tics in Schoolchildren in Central Spain: A Population-Based Study","volume":"45","author":"Cubo","year":"2011","journal-title":"Pediatr. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1469-8749.2000.tb00346.x","article-title":"An international perspective on Tourette syndrome: Selected findings from 3,500 individuals in 22 countries","volume":"42","author":"Freeman","year":"2000","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1469-7610.1994.tb01209.x","article-title":"Annotation: Gilles de la Tourette syndrome-an update","volume":"35","author":"Robertson","year":"1994","journal-title":"J. Child Psychol. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0733-8619(05)70320-0","article-title":"Epidemiology of Tourette syndrome","volume":"15","author":"Tanner","year":"1997","journal-title":"Neurol. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","article-title":"European clinical guidelines for Tourette syndrome and other tic disorders. Part II: Pharmacological treatment","volume":"20","author":"Roessner","year":"2011","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/026988119300700411","article-title":"Effective treatment of Tourette\u2019s syndrome with marijuana","volume":"7","author":"Hemming","year":"1993","journal-title":"J. Psychopharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00004714-198812000-00021","article-title":"Marijuana and Tourette\u2019s syndrome","volume":"8","author":"Sandyk","year":"1988","journal-title":"J. Clin. Psychopharmacol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial","volume":"64","author":"Schneider","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): A randomized crossover trial","volume":"35","author":"Schneider","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study","volume":"197","author":"Morgan","year":"2010","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.2165\/11585260-000000000-00000","article-title":"Role of cannabinoids in the treatment of pain and (painful) spasticity","volume":"70","author":"Karst","year":"2010","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/1039856216663737","article-title":"Severe motor and vocal tics controlled with Sativex\u00ae","volume":"24","author":"Trainor","year":"2016","journal-title":"Australas. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00004583-198907000-00015","article-title":"The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity","volume":"28","author":"Leckman","year":"1989","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_16","unstructured":"Shapiro, A., Shapiro, E., Young, J., and Feinberg, T. (1988). Signs, symptoms, and clinical course. Gilles de la Tourette Syndrome, Raven."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/1531-8257(199905)14:3<502::AID-MDS1020>3.0.CO;2-G","article-title":"Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale","volume":"14","author":"Goetz","year":"1999","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00004703-200512000-00001","article-title":"Premonitory Urge for Tics Scale (PUTS): Initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders","volume":"26","author":"Woods","year":"2005","journal-title":"J. Dev. Behav. Pediatr. JDBP"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1212\/01.wnl.0000327890.02893.61","article-title":"The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): Development and validation","volume":"71","author":"Cavanna","year":"2008","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/ajp.156.3.495","article-title":"Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol","volume":"156","author":"Schneider","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.psychres.2011.05.033","article-title":"Cannabinoids improve driving ability in a Tourette\u2019s patient","volume":"190","author":"Brunnauer","year":"2011","journal-title":"Psychiatry Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","article-title":"Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report","volume":"30","author":"Hasan","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1600-0447.1998.tb10127.x","article-title":"Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome","volume":"98","author":"Kolbe","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_24","unstructured":"M\u00fcller-Vahl, K. (2014). Tourette-Syndrom und andere Tic-Erkrankungen im Kindes\u2014Und Erwachsenenalter, Auflage; Medizinisch Wissenschaftliche Verlagsgesellschaft. [2nd ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fnins.2016.00416","article-title":"Aripiprazole improves associated comorbid Conditions in addition to Tics in adult patients with Gilles de la Tourette Syndrome","volume":"10","author":"Gerasch","year":"2016","journal-title":"Front. Neurosci."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/7\/5\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:33:48Z","timestamp":1760207628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/7\/5\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["brainsci7050047"],"URL":"https:\/\/doi.org\/10.3390\/brainsci7050047","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}